Mr. Doug Janzen reports

AEQUUS ANNOUNCES GIOVANNI DI GENOVA JOINING BOARD OF DIRECTORS

Giovanni Di Genova has agreed to join the Aequus Pharmaceuticals Inc. board of directors, subject to the completion of his PIF and Toronto Stock Exchange approval, effective Friday, Sept. 12, 2025.

"Aequus is pleased to welcome Giovanni Di Genova as a new director and we are eager to work with him on the future ahead," said Doug Janzen, Aequus chairman and chief executive officer.

Mr. Di Genova earned his bachelor of science and bachelor of pharmacy from McGill University and Universite de Montreal, respectively. He began his career in the specialty compounding pharmacy and pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas, including ophthalmology, oncology, gastrointestinal, neurological, infectious and autoimmune diseases. He has held positions in both innovative and generic pharmaceutical organizations, with roles in API/materials management, production, sales, marketing and business development. He has a proven record in strategy and operations, including strong business development experience with M&A (merger and acquisition), licensing, co-development and supply agreements. Mr. Di Genova started his career at Ayerst and PharmaScience, and most recently served as chief executive officer and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing and distribution of high-barrier-to-market niche pharmaceuticals.

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals is a specialty pharmaceutical company, with a focus on commercializing value-added products in specialty therapeutic areas in the Canadian market.

We seek Safe Harbor.